ArticleJournal of thoracic disease2025
Low-intensity pulsed ultrasound in acute multiple rib fracture-a prospective analysis, randomized controlled trial and pilot study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-intensity pulsed ultrasound (LIPUS) is a non-invasive modality that promotes bone healing by stimulating callus formation and enhancing regeneration. Although its efficacy in long bone fractures is well established, its role in managing acute multiple rib fractures (MRFs) remains unclear. This study aimed to investigate whether LIPUS can improve fracture healing and pain control in patients with acute MRF following thoracic trauma. Methods: This prospective, randomized study aimed to evaluate the efficacy of LIPUS in promoting bone healing through callus formation and modifying pain patterns in patients with acute MRF. The primary objective was to determine whether LIPUS could improve fracture healing outcomes and provide superior pain control compared to conventional treatment. Between April 1, 2024 and October 31, 2024, twenty adult patients with rib fractures were enrolled and randomly assigned to one of two groups: (I) the LIPUS group (n=10), who received standard rib fracture care supplemented with LIPUS therapy; and (II) the conventional group (n=10), who received standard care alone. Clinical and demographic characteristics, outcomes, and surgical complications were assessed. The primary endpoints included the effect of LIPUS on clinical manifestations and pain control in acute MRF. Results: Twenty eligible patients (10 males, 10 females) were included. Demographic and clinical characteristics were comparable. The average age was lower in the LIPUS group, but not significantly (64.40±8.97 Conclusions: LIPUS appears to be a viable and effective treatment option for acute MRF. It may alleviate pain, reduce complications, and improve clinical outcomes, particularly in patients with traumatic hemothorax or pneumothorax. Trial Registration: This study was registered with the Clinical Research Information Service (CRIS: a non-profit online registry for clinical trials and research conducted in South Korea) under the reference number KCT0010838.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.